Gut microbiota-derived TMA/TMAO and IRAK4 signaling in type 2 diabetes: Current evidence, knowledge gaps and future therapeutic opportunities.
- DOI
- 10.1016/j.intimp.2026.117240
- Published
- 2026 Aug 13
- Container
- International immunopharmacology
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.intimp.2026.117240,
title = {Gut microbiota-derived TMA/TMAO and IRAK4 signaling in type 2 diabetes: Current evidence, knowledge gaps and future therapeutic opportunities.},
author = {Sarma AD and Devi M and Kumar D and Choudhary N},
year = {2026},
journal = {International immunopharmacology},
doi = {10.1016/j.intimp.2026.117240},
url = {https://doi.org/10.1016/j.intimp.2026.117240}
}RIS
TY - JOUR TI - Gut microbiota-derived TMA/TMAO and IRAK4 signaling in type 2 diabetes: Current evidence, knowledge gaps and future therapeutic opportunities. AU - Sarma AD AU - Devi M AU - Kumar D AU - Choudhary N PY - 2026 JO - International immunopharmacology DO - 10.1016/j.intimp.2026.117240 UR - https://doi.org/10.1016/j.intimp.2026.117240 ER -
APA
AD, S., M, D., D, K., & N, C. (2026). Gut microbiota-derived TMA/TMAO and IRAK4 signaling in type 2 diabetes: Current evidence, knowledge gaps and future therapeutic opportunities.. International immunopharmacology. https://doi.org/10.1016/j.intimp.2026.117240
Source records
- pubmed · retrieved 2026-09-25T19:23:24.770Z
- europe-pmc · retrieved 2026-09-25T19:23:24.796Z